Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

IBD not linked to risk of hypertensive disorders of pregnancy overall (opens in a new tab)

medicalxpress.com · 2026-09-24

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 4 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All four claims match what the study reports.

  • 4 supported
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Analytic approach: generalized estimating equations with adjustment for age, first-trimester BMI and blood pressure, insurance, race, and parity.

    The story mentions electronic health records and the cohort design, but the supplied presentation does not indicate that the model used GEE or list the covariate adjustment set.

    From Single-center retrospective EHR cohort; Retrospective EHR cohort; secondary outcome GEE logistic regression

  • Important limitation: multiple secondary outcomes were assessed, and the abstract does not report correction for multiple comparisons; secondary findings such as pre-eclampsia should be interpreted cautiously.

    The story reports the secondary associations but does not mention multiplicity or the secondary nature of these analyses as a caveat.

    From Retrospective EHR cohort; secondary outcome GEE logistic regression

6 things the story did carry across
  • Primary outcome: IBD was not statistically significantly associated with any hypertensive disorder of pregnancy overall, defined as gestational hypertension or pre-eclampsia, with aOR 1.21, 95% CI 0.81–1.82.
  • Secondary hypertensive subtypes: IBD was associated with increased adjusted odds of pre-eclampsia but not gestational hypertension.
  • Other secondary outcomes: IBD was associated with preterm delivery, small for gestational age birth weight, and cesarean delivery, but not with other listed secondary outcomes in the abstract.
  • Study design and population: single-center retrospective EHR cohort of singleton deliveries from 1998–2016, including 364 pregnancies with IBD and 45,048 without IBD.
  • Important limitation: the study was single-center and retrospective, which may limit generalizability and increase susceptibility to EHR ascertainment issues.
  • Precision limitation: the IBD group was relatively small compared with the non-IBD group, potentially affecting precision for some outcomes.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataEstimate whether inflammatory bowel disease (IBD) is associated with hypertensive disorders of pregnancy overall (composite outcome: gestational hypertension or pre-eclampsia) in a single-center EHR pregnancy cohort.Single-center retrospective EHR cohortExpand

In plain English

Single-center retrospective EHR cohort of singleton deliveries (1998–2016) estimated the association between maternal IBD and any hypertensive disorder of pregnancy (composite of gestational hypertension or pre-eclampsia) using GEE models adjusted for age, first-trimester BMI and blood pressure, insurance, race, and parity. The adjusted odds ratio for the primary composite outcome was 1.21 (95% CI 0.81–1.82; P = 0.35), indicating no statistically significant association in this cohort.

Key findings

  • In this single-center EHR cohort, IBD was not associated with the primary composite outcome of any hypertensive disorder of pregnancy (gestational hypertension or pre-eclampsia).aOR 1.21 (95% CI 0.81–1.82), P = 0.35
“We performed a single-center cohort study using electronic health records of singleton pregnancies delivered 1998-2016.”
2secondary dataEvaluate associations between IBD and specific adverse pregnancy outcomes, including pre-eclampsia vs gestational hypertension separately and other obstetric/neonatal outcomes (e.g., preterm delivery, SGA, cesarean delivery).Retrospective EHR cohort; secondary outcome GEE logistic regressionExpand

In plain English

Single-center retrospective EHR cohort (singleton deliveries 1998–2016) analyzing associations between maternal IBD and multiple secondary obstetric and neonatal outcomes using GEE logistic regression adjusted for age, first-trimester BMI and blood pressure, insurance, race, and parity. Among 364 IBD pregnancies and 45,048 non-IBD pregnancies, IBD was associated with higher adjusted odds of pre-eclampsia, preterm delivery, small for gestational age birth weight, and cesarean delivery, but not with gestational hypertension or other listed secondary outcomes.

Key findings

  • IBD was associated with increased odds of pre-eclampsia.aOR 1.65 (95% CI 1.02–2.68)
  • IBD was not associated with gestational hypertension.aOR 0.82 (95% CI 0.42–1.57)
“Secondary outcomes included gestational hypertension, pre-eclampsia, preterm delivery, gestational diabetes, severe perineal laceration, and small or large for gestational age birth weight.”
What this piece can’t prove
  • Single-center, retrospective EHR cohort which may limit generalizability.
  • Relatively small number of IBD pregnancies (n=364) compared with non-IBD pregnancies, potentially affecting precision for some outcomes.
  • Multiple secondary outcomes were assessed; abstract does not report correction for multiple comparisons.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

Candidate

S1455 Real-World Comparative Effectiveness of Vedolizumab vs Upadacitinib and Risankizumab for Crohn’s Disease Through 52 Weeks

American Journal of Gastroenterology · 2025 · Crossref

And 32 more candidates considered.